Drugs.com - Clinical Trials

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

South San Francisco, CA -- April 3, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s...

Apr 8, 2025 - 03:58
 0
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
South San Francisco, CA -- April 3, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s...
Read More

Tags:

Previous Article

Theravance Biopharma Presents Two New Ampreloxetine Analyses

Next Article

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases wi...

Related Posts

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Zydus Announces USFDA Orphan Drug Designation to Usnofl...

Feb 9, 2025  0

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Po...

Feb 9, 2025  0

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate...

Apr 10, 2025  0